

John W. Eikelboom

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9156826/john-w-eikelboom-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

651
papers

61,174
citations

105
h-index

239
g-index

738
ext. papers

72,124
ext. citations

10.5
avg, IF

7.59
L-index

#	Paper	IF	Citations
651	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
650	Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery.. <i>Trials</i> , 2022 , 23, 101	2.8	1
649	Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial.. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022 , 28, 10760296211073922	3.3	
648	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study.. <i>TH Open</i> , 2022 , 6, e10-e17	2.7	2
647	Effect of a Perioperative Hypotension-Avoidance Strategy Versus a Hypertension-Avoidance Strategy on the Risk of Acute Kidney Injury: A Clinical Research Protocol for a Substudy of the POISE-3 Randomized Clinical Trial.. <i>Canadian Journal of Kidney Health and Disease</i> , 2022 , 9, 20543581211069225	2.3	
646	Aortic plaque burden predicts vascular events in patients with cardiovascular disease: The EAST-NOGA study. <i>Journal of Cardiology</i> , 2022 , 79, 144-152	3	1
645	Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12650	5.1	1
644	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2.. <i>Circulation</i> , 2022 , 145, 626-628	16.7	1
643	Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and knee Replacement (PEPPER): the PEPPER trial protocol.. <i>BMJ Open</i> , 2022 , 12, e060000	3	2
642	Tranexamic Acid in Patients Undergoing Noncardiac Surgery.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	6
641	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , 2021 , 4, e2141328	10.4	8
640	Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 1	5.1	
639	Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on-treatment platelet reactivity: the OPTimal Management of Antithrombotic Agents (OPTIMA)-2 Trial. <i>British Journal of Haematology</i> , 2021 ,	4.5	1
638	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021 , 23, 748-756	3.9	2
637	Quality of early evidence on the pathogenesis, diagnosis, prognosis and treatment of COVID-19. <i>BMJ Evidence-Based Medicine</i> , 2021 , 26, 302-306	2.7	7
636	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 21-29	16.2	12
635	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. <i>Cardiovascular Research</i> , 2021 , 117, 2030-2044	9.9	4

634	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, e71	6.4	1
633	Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reduction.. <i>Med</i> , 2021 , 2, 233-242	31.7	
632	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
631	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2021 , 42, 2765-2775	9.5	31
630	Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1903-1921	15.1	84
629	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Circulation</i> , 2021 , 143, 1863-1873	16.7	6
628	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021 , 107, 1130-1137	5.1	0
627	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	1
626	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome. <i>European Cardiology Review</i> , 2021 , 16, e26	3.9	2
625	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021 , 52, 2096-2105	6.7	5
624	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021 , 149, 27-35	3	3
623	Reply: All Fat Is Not Created Equal: The Problem of Defining Obesity in the Elderly. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2757	15.1	
622	What is the role of growth-differentiation factor-15 in biomarker-based prediction of mortality in patients with atrial fibrillation?. <i>European Journal of Internal Medicine</i> , 2021 , 88, 23-24	3.9	0
621	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021 , 117, 576-584	9.9	10
620	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021 , 117, 942-949	9.9	7
619	Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety?. <i>Future Cardiology</i> , 2021 , 17, 175-182	1.3	1
618	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021 , 126, 163-171	5.4	9
617	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021 , 126, 172-180	5.4	3

616	Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 118-120	7	1
615	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 518-528	7	2
614	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 511-525	15.1	3
613	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. <i>American Heart Journal</i>	4.9	2
612	Plasma Rivaroxaban Level to Identify Patients at Risk of Drug Overexposure: Is a Single Measurement of Drug Level Reliable?. <i>TH Open</i> , 2021 , 5, e84-e88	2.7	1
611	Direct Oral Anticoagulant Reversal for Management of Bleeding and Emergent Surgery 2021 , 71-91		
610	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , 2021 , 143, 583-596	16.7	31
609	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1097-1106	7	5
608	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 14-23	15.1	9
607	Elevated plasma levels of NT-proBNP in ambulatory patients with peripheral arterial disease. <i>PLoS ONE</i> , 2021 , 16, e0253792	3.7	
606	Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1815-1823	2.8	0
605	Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?. <i>European Heart Journal</i> , 2021 , 42, 3143-3145	9.5	4
604	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
603	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021 , 331, 38-44	3.1	
602	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2726-2737	15.4	5
601	Risk stratification of cardiovascular complications using CHADS-VASc and CHADS scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021 , 337, 9-15	3.2	0
600	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 859-866	15.1	4
599	Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1091-1102	5.5	0

598	Ross for Valve replacement In AdULts (REVIVAL) pilot trial: rationale and design of a randomised controlled trial. <i>BMJ Open</i> , 2021 , 11, e046198	3	1
597	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery: A Post Hoc Analysis From the COMPASS Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	10
596	Direct oral anticoagulant dose selection: Challenging cases. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2680-2686	15.4	0
595	Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. <i>Kidney International</i> , 2021 , 100, 1199-1207	9.9	2
594	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e018984	6	9
593	Fatty acid binding protein 3 is associated with peripheral arterial disease. <i>JVS Vascular Science</i> , 2020 , 1, 168-175	1.3	4
592	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020 , 41, 2848-2859	9.5	11
591	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1004-1024	7	147
590	The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. <i>Circulation</i> , 2020 , 142, 40-48	16.7	29
589	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020 , 141, 1141-1151	16.7	21
588	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , 2020 , 141, 1841-1854	16.7	53
587	Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis. <i>Neurology</i> , 2020 , 95, e480-e487	6.5	1
586	Plasma Levels of Protein Z in Ischemic Stroke: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 815-822	7	1
585	Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 194-196	7	
584	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 242-257	14.8	41
583	Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 484-494	7	16
582	Anticoagulation for Stroke Prevention in Patients With Atrial Fibrillation and End-Stage Renal Disease-First, Do No Harm. <i>JAMA Network Open</i> , 2020 , 3, e202237	10.4	5
581	Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020 , 46, 908-918	5.3	4

580	Reply. <i>Gastroenterology</i> , 2020 , 158, 1175-1176	13.3	1
579	Reply. <i>Gastroenterology</i> , 2020 , 158, 285-286	13.3	
578	Selection Bias, Orthopaedic Style: Knowing What We Don't Know About Aspirin. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020 , 102, 631-633	5.6	5
577	Mortality benefits of thromboprophylaxis. <i>Lancet Haematology</i> , 2020 , 7, e783	14.6	
576	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020 , 41, 4037-4046	9.5	52
575	2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 594-622	15.1	69
574	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1323-1329	7	11
573	Direct oral anticoagulants: evidence and unresolved issues. <i>Lancet, The</i> , 2020 , 396, 1767-1776	40	32
572	Plasma Apixaban Levels in Patients Treated Off Label With the Lower Dose. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2906-2907	15.1	4
571	Is aspirin safer than a direct oral anticoagulant for patients with atrial fibrillation at high risk of bleeding?. <i>European Journal of Internal Medicine</i> , 2020 , 79, 25-26	3.9	
570	Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. <i>Future Cardiology</i> , 2020 , 16, 597-611	1.3	
569	Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial. <i>Pilot and Feasibility Studies</i> , 2020 , 6, 104	1.9	3
568	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
567	Colchicine in Patients with Chronic Coronary Disease. <i>New England Journal of Medicine</i> , 2020 , 383, 1838-1847	39.7	396
566	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020 , 3, e2015943	10.4	2
565	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1468-1483	15.1	16
564	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. <i>JAMA Neurology</i> , 2020 , 77, 43-48	17.2	25
563	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 296-307	3.9	17

562	COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2950-2973	15.1	1682
561	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019 , 12, e007545	6.4	12
560	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019 , 40, 3771-3778a	9.5	19
559	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019 , 140, 1451-1459	16.7	22
558	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
557	Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1760-1768	15.1	12
556	Reduction in Mortality following Elective Major Hip and Knee Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 668-674	7	15
555	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 576-585	7	6
554	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72
553	Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2769-2772	15.1	3
552	Pulmonary embolism: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019 , 211, 82-87	4	7
551	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019 , 140, 529-537	16.7	50
550	Deep vein thrombosis: update on diagnosis and management. <i>Medical Journal of Australia</i> , 2019 , 210, 516-524	4	33
549	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019 , 40, 2632-2653	9.5	169
548	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 140, 240-261	16.7	183
547	Reply: Rivaroxaban Plus Aspirin After CABG: More Evidence Is Needed. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2360	15.1	
546	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2243-2250	15.1	24
545	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. <i>Circulation</i> , 2019 , 139, 2846-2856	16.7	9

544	External applicability of the COMPASS trial: the Western Denmark Heart Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 192-199	6.4	7
543	How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism. <i>Blood</i> , 2019 , 133, 2269-2278	2.2	8
542	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
541	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019 , 380, 1326-1335	59.2	431
540	The Ross procedure versus prosthetic and homograft aortic valve replacement: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2019 , 55, 247-255	3	12
539	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
538	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019 , 157, 682-691.e2	13.3	181
537	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3271-3280	15.1	56
536	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019 , 157, 403-412.e5	13.3	62
535	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 431-497	5.1	5
534	Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. <i>BMJ, The</i> , 2019 , 367, l5476	5.9	34
533	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2019 , 218, 46-56	4.9	30
532	Diabetes Mellitus Is Associated With Increased Risk of Ischemic Stroke in Patients With and Without Coronary Artery Disease. <i>Stroke</i> , 2019 , 50, 3347-3354	6.7	13
531	Fifty years of research on antithrombotic therapy: Achievements and disappointments. <i>European Journal of Internal Medicine</i> , 2019 , 70, 1-7	3.9	9
530	How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?. <i>Kardiologia Polska</i> , 2019 , 77, 661-669	0.9	5
529	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. <i>Blood</i> , 2019 , 134, 711-711	2.2	0
528	Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study. <i>Blood</i> , 2019 , 134, 2434-2434	2.2	0
527	Reversal of the antiplatelet effect of ticagrelor by simulated platelet transfusion. <i>Transfusion</i> , 2019 , 59, 1850-1856	2.9	4

526	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 720-728	59.2	322
525	Review: After PCI with DESs, long- and standard-term DAPT increase some adverse outcomes vs short-term DAPT. <i>Annals of Internal Medicine</i> , 2019 , 171, JC54	8	
524	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence. <i>Future Cardiology</i> , 2019 , 15, 395-404	1.3	2
523	Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. <i>The Cochrane Library</i> , 2019 ,	5.2	1
522	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019 , 218, 100-109	4.9	4
521	How Did We Get Here?: A Historical Review and Critical Analysis of Anticoagulation Therapy Following Mechanical Valve Replacement. <i>Circulation</i> , 2019 , 140, 1933-1942	16.7	5
520	The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. <i>International Journal of Cardiology</i> , 2019 , 278, 7-13	3.2	11
519	The association between blood donor sex and age and transfusion recipient mortality: an exploratory analysis. <i>Transfusion</i> , 2019 , 59, 482-491	2.9	21
518	Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1-11	5	17
517	Stroke prevention in AF: Of Asians and non-Asians. <i>European Heart Journal</i> , 2019 , 40, 1528-1530	9.5	3
516	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e010107	6	12
515	Antiplatelet Therapy versus Anticoagulation after Surgical Bioprosthetic Aortic Valve Replacement: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 328-339	7	6
514	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 121-130	15.1	46
513	Comparison of Frequency of Ischemic Stroke in Patients With Versus Without Coronary Heart Disease and Without Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019 , 123, 153-158	3	7
512	NOACs only for those who cannot tolerate a VKA: where is the evidence?. <i>Acta Cardiologica</i> , 2019 , 74, 17-20	0.9	
511	Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. <i>Journal of Cardiovascular Surgery</i> , 2018 , 59, 128-139	0.7	6
510	International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 906-913	7	8
509	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018 , 39, 464-473	9.5	25

508	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018 , 34, 295-302	3.8	17
507	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. <i>European Heart Journal</i> , 2018 , 39, 477-485	9.5	63
506	Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. <i>British Journal of Anaesthesia</i> , 2018 , 120, 645-656	5.4	99
505	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. <i>American Heart Journal</i> , 2018 , 198, 169-177	4.9	6
504	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018 , 39, 750-757a	9.5	56
503	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2306-2315	15.1	173
502	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018 , 199, 59-67	4.9	15
501	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. <i>Circulation</i> , 2018 , 138, 527-536	16.7	164
500	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018 , 39, 3973-3979	9.5	79
499	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 255-267	15.1	36
498	Hemodynamic outcomes of the Ross procedure versus other aortic valve replacement: a systematic review and meta-analysis. <i>Journal of Cardiovascular Surgery</i> , 2018 , 59, 462-470	0.7	10
497	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2325-2334	40	142
496	Quantifying immature platelets as markers of increased platelet production after coronary artery bypass grafting surgery. <i>European Journal of Haematology</i> , 2018 , 101, 362-367	3.8	4
495	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018 , 13, e0191592	3.7	53
494	Impact of cost on use of non-vitamin K antagonists in atrial fibrillation patients in Ontario, Canada. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 310-315	5.1	2
493	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018 , 132, LBA-1-LBA-1	2.2	9
492	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204
491	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414

490	Anticoagulant-Related Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 2787-2793	38
489	Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS. <i>Future Cardiology</i> , 2018 , 14, 443-453	1.3 3
488	Response to: Unacceptable conflicts of interest (Br J Anaesth 2018; 121: 1183). <i>British Journal of Anaesthesia</i> , 2018 , 121, 1183-1184	5.4
487	In Vitro Reversal of the Anti-Aggregant Effect of Ticagrelor Using Untreated Platelets. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1895-1901	7 8
486	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018 , 70, 828-835	1.6 10
485	Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. <i>Vox Sanguinis</i> , 2017 , 112, 268-278	3.1 35
484	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017 , 103, 1015-1023	5.1 58
483	Clinical implications of reversal agents for direct oral anticoagulants. <i>Future Cardiology</i> , 2017 , 13, 153-159	3 7
482	Resuming warfarin after intracranial hemorrhage in patients with AF was linked to reduced mortality. <i>Annals of Internal Medicine</i> , 2017 , 166, JC70	8
481	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017 , 190, 94-103	4.9 34
480	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035	3.8 97
479	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 566-574	16.2 72
478	Short-Term versus Long-Term Blood Storage. <i>New England Journal of Medicine</i> , 2017 , 376, 1092-3	59.2 4
477	Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 291-301	5.1 30
476	A Test in Context: D-Dimer. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2411-2420	15.1 173
475	Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. <i>Lancet Haematology</i> , 2017 , 4, e544-e552	14.6 27
474	HERDOO2 identified women at low risk for recurrence after 5 to 12 mo of anticoagulation for a first unprovoked VTE. <i>Annals of Internal Medicine</i> , 2017 , 167, JC33	8 1
473	Bleeding impacting mortality after noncardiac surgery: a protocol to establish diagnostic criteria, estimate prognostic importance, and develop and validate a prediction guide in an international prospective cohort study. <i>CMAJ Open</i> , 2017 , 5, E594-E603	2.5 6

472	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017 , 1, e82-e91	2.7	6
471	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2017 , 38, 852-859	9.5	50
470	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017 , 38, 860-868	9.5	75
469	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
468	Assessing renal function in patients receiving DOACs: Cockcroft-Gault versus estimated glomerular filtration rate. <i>Thrombosis Research</i> , 2017 , 157, 165-166	8.2	6
467	In Reply. <i>Anesthesiology</i> , 2017 , 127, 401-402	4.3	
466	2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 3042-3067	15.1	228
465	Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. <i>New England Journal of Medicine</i> , 2017 , 377, 431-441	59.2	639
464	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2135-2145	7	37
463	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017 , 1, e139-e145	2.7	15
462	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016 , 134, 1697-1707	16.7	58
461	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016 , 375, 1131-41	59.2	580
460	Response by Weitz and Eikelboom to Letter Regarding Article, "Urgent Need to Measure Effects of Direct Oral Anticoagulants". <i>Circulation</i> , 2016 , 134, e498	16.7	
459	Urgent Need to Measure Effects of Direct Oral Anticoagulants. <i>Circulation</i> , 2016 , 134, 186-8	16.7	34
458	Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. <i>New England Journal of Medicine</i> , 2016 , 375, 1937-1945	59.2	202
457	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	73
456	Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchema Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. <i>Anesthesiology</i> , 2016 , 125, 1121-1129	4.3	16
455	Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study. <i>European Journal of Internal Medicine</i> , 2016 , 33, 55-9	3.9	22

454	Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1108-16	3.8	6
453	Letter to the Editor: Managing Dabigatran-Related Bleeding. <i>Journal of Intensive Care Medicine</i> , 2016 , 31, 70-1	3.3	
452	Dabigatran etexilate and reduction in serum apolipoprotein B. <i>Heart</i> , 2016 , 102, 57-62	5.1	30
451	Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 90-8	5.1	7
450	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection: BRUISE CONTROL INFECTION Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1300-8	15.1	101
449	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016 , 139, 77-81	8.2	23
448	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1332-1339	3.8	5
447	Rationale and Design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An International Pragmatic Randomized Trial. <i>Transfusion Medicine Reviews</i> , 2016 , 30, 25-9	7.4	13
446	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016 , 140, 81-88	8.2	10
445	Red blood cell processing methods and in-hospital mortality: a transfusion registry cohort study. <i>Lancet Haematology</i> , 2016 , 3, e246-54	14.6	48
444	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016 , 18, 973-8	3.9	16
443	Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016 , 152, 245-251.e4	1.5	24
442	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016 , 173, 102-7	4.9	28
441	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016 , 45, 77-83	3	72
440	Bleeding in Patients with Atrial Fibrillation Treated with Different Doses of Direct Oral Anticoagulants and Vitamin K Antagonists: A Population-Based Study. <i>Blood</i> , 2016 , 128, 2617-2617	2.2	2
439	Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 257-70	7	11
438	D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 921-30	7	28
437	D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 921-930	7	29

436	Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. <i>Journal of Blood Transfusion</i> , 2016 , 2016, 9316385		12
435	Laboratory measurement of the direct oral anticoagulants. <i>British Journal of Haematology</i> , 2016 , 172, 315-36	4.5	65
434	Exposure to ABO-nonidentical blood associated with increased in-hospital mortality in patients with group A blood. <i>Transfusion</i> , 2016 , 56, 550-7	2.9	14
433	Stroke: How good is aspirin for patients with acute brain ischaemia?. <i>Nature Reviews Neurology</i> , 2016 , 12, 434-5	15	
432	Dabigatran in clinical practice: Contemporary overview of the evidence. <i>International Journal of Cardiology</i> , 2016 , 220, 417-28	3.2	6
431	Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention. <i>Circulation</i> , 2016 , 133, 2094-8	16.7	18
430	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016 , 387, 2302-2311	4.0	272
429	Rapid reversal of haematoma expansion associated with vitamin K antagonists. <i>Lancet Neurology, The</i> , 2016 , 15, 535-7	24.1	2
428	Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation. <i>Critical Care</i> , 2016 , 20, 115	10.8	35
427	Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. <i>Circulation Research</i> , 2016 , 118, 1409-24	15.7	76
426	Trends in incidence and prevalence of hospitalization for atrial fibrillation and associated mortality in Western Australia, 1995-2010. <i>International Journal of Cardiology</i> , 2016 , 208, 19-25	3.2	26
425	Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. <i>American Journal of Medicine</i> , 2016 , 129, e35-6	2.4	23
424	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , 2016 , 178, 145-50	4.9	39
423	Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. <i>Blood</i> , 2016 , 127, 400-10	2.2	81
422	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. <i>American Journal of Medicine</i> , 2016 , 129, S33-S40	2.4	54
421	Measurement of Dabigatran Drug Levels to Manage Patients Taking Interacting Drugs: A Case Report. <i>American Journal of Medicine</i> , 2016 , 129, e247-8	2.4	11
420	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <i>American Journal of Emergency Medicine</i> , 2016 , 34, 3-8	2.9	17
419	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016 , 17, 1425-39	2.6	18

418	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015 , 36, 281-7a	9.5	196
417	A systematic review of contemporary trials of anticoagulants in orthopaedic thromboprophylaxis: suggestions for a radical reappraisal. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 231-9	5.1	22
416	ACP Journal Club: mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2015 , 162, JC4	8	
415	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes. <i>Circulation</i> , 2015 , 132, 796-803	16.7	62
414	Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. <i>Kidney International</i> , 2015 , 88, 576-83	9.9	21
413	Idarucizumab for Dabigatran Reversal. <i>New England Journal of Medicine</i> , 2015 , 373, 511-20	59.2	1223
412	Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 618-27		41
411	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015 , 36, 1454-62	9.5	83
410	Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. <i>Pediatric Nephrology</i> , 2015 , 30, 1519-27	3.2	41
409	Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin. <i>Evidence-Based Medicine</i> , 2015 , 20, 117		
408	Cardiac biomarkers and acute kidney injury after cardiac surgery. <i>Pediatrics</i> , 2015 , 135, e945-56	7.4	37
407	Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants. <i>Expert Review of Cardiovascular Therapy</i> , 2015 , 13, 1213-23	2.5	1
406	Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 3123-32	12.7	102
405	Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 23-34	5.1	21
404	Reply: Anticoagulant-Related Nephropathy. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2682	5.1	0
403	Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2015 , 15, 96	2.3	77
402	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 625-32	7	158
401	Exploratory studies on the age of transfused blood and in-hospital mortality in patients with cardiovascular diagnoses. <i>Transfusion</i> , 2015 , 55, 364-72	2.9	19

400	Lack of consistency in the relationship between asymptomatic DVT detected by venography and symptomatic VTE in thromboprophylaxis trials. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 1049-57	7	21
399	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 933-44	7	9
398	Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. <i>Vascular Health and Risk Management</i> , 2015 , 11, 343-51	4.4	58
397	Genotype-guided versus standard vitamin K antagonist dosing algorithms in patients initiating anticoagulation. A systematic review and meta-analysis. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 768-77	7	31
396	Timing the First Postoperative Dose of Anticoagulants: Lessons Learned From Clinical Trials. <i>Chest</i> , 2015 , 148, 587-595	5.3	11
395	Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 198-205	7	119
394	Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2481-93	15.1	130
393	Idarucizumab: The Antidote for Reversal of Dabigatran. <i>Circulation</i> , 2015 , 132, 2412-22	16.7	125
392	Risk of Stent Thrombosis and Major Bleeding with Bivalirudin Compared with Active Control: A Systematic Review and Meta-analysis of Randomized Trials. <i>Thrombosis Research</i> , 2015 , 136, 1087-98	8.2	11
391	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015 , 6, 267-277	1.8	0
390	Management of bleeding with oral anticoagulants in patients with atrial fibrillation. <i>Hamostaseologie</i> , 2015 , 35, 351-7	1.9	
389	Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. <i>Circulation</i> , 2014 , 129, 961-70	16.7	293
388	Clonidine in patients undergoing noncardiac surgery. <i>New England Journal of Medicine</i> , 2014 , 370, 1504-13	13.2	219
387	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 2242-8a	9.5	34
386	Novel oral anticoagulants: a focused review for stroke physicians. <i>International Journal of Stroke</i> , 2014 , 9, 71-8	6.3	8
385	Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 362-71	5.1	11
384	Colchicine for secondary prevention of cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 391	6	25
383	Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 45-52	2.6	30

382	Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation. <i>Stroke</i> , 2014 , 45, 3637-42	6.7	15
381	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014 , 124, 689-99	2.2	26
380	Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation</i> , 2014 , 130, 1062-71	16.7	190
379	Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. <i>Neurology: Clinical Practice</i> , 2014 , 4, 96-98	1.7	1
378	Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. <i>Stroke</i> , 2014 , 45, 2127-30	6.7	10
377	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. <i>BMJ Open</i> , 2014 , 4, e005674	3	2
376	Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. <i>Canadian Journal of Cardiology</i> , 2014 , 30, 381-4	3.8	19
375	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , 2014 , 120, 564-78	4.3	509
374	ACP Journal Club. Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014 , 160, JC4	8	
373	Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 918-23	7	46
372	Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 10-3	7	8
371	Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 1120-8	7	16
370	Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". <i>Circulation</i> , 2014 , 130, e195	16.7	1
369	Betrixaban (PRT054021): pharmacology, dose selection and clinical studies. <i>Future Cardiology</i> , 2014 , 10, 43-52	1.3	27
368	Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". <i>Circulation</i> , 2014 , 130, e95	16.7	
367	Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study". <i>Circulation</i> , 2014 , 130, e85	16.7	1
366	Prevention of thromboembolism in the patient with acute coronary syndrome and atrial fibrillation: the clinical dilemma of triple therapy. <i>Current Opinion in Cardiology</i> , 2014 , 29, 1-9	2.1	6
365	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014 , 35, 1856-63	9.5	20

364	New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 798-807	7	38
363	The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 221-229	15.1	585
362	Efficacy and safety of warfarin vs. antiplatelet therapy in patients with systolic heart failure and sinus rhythm: a systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Stroke</i> , 2014 , 9, 199-206	6.3	10
361	Reply: regarding the effect of dabigatran plasma concentrations. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2885-6	15.1	3
360	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 435-42	5.1	9
359	A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. <i>European Journal of Epidemiology</i> , 2014 , 29, 181-90	12.1	78
358	Aspirin in patients undergoing noncardiac surgery. <i>New England Journal of Medicine</i> , 2014 , 370, 1494-503	39.2	525
357	Bleeding in Patients with Atrial Fibrillation Treated with Non Vitamin K Antagonist Oral Anticoagulants: A Population-Based Study. <i>Blood</i> , 2014 , 124, 343-343	2.2	2
356	Utilization of Universal Group O Blood By Non Group O Recipients. <i>Blood</i> , 2014 , 124, 5103-5103	2.2	1
355	Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. <i>PLoS ONE</i> , 2014 , 9, e88131	3.7	6
354	Approach to the new oral anticoagulants in family practice: part 1: comparing the options. <i>Canadian Family Physician</i> , 2014 , 60, 989-95	0.9	11
353	Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. <i>Canadian Family Physician</i> , 2014 , 60, 997-1001	0.9	10
352	New oral anticoagulants in elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013 , 26, 215-24	4.2	53
351	Novel oral anticoagulants for atrial fibrillation. <i>Current Atherosclerosis Reports</i> , 2013 , 15, 344	6	13
350	Targeting the unstable plaque in acute coronary syndromes. <i>Clinical Therapeutics</i> , 2013 , 35, 1099-107	3.5	15
349	Dabigatran versus warfarin in patients with mechanical heart valves. <i>New England Journal of Medicine</i> , 2013 , 369, 1206-14	59.2	919
348	Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1042-7	3.8	18
347	Adherence to anticoagulant treatment with dabigatran in a real-world setting. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1295-9	15.4	78

346	Management and outcomes of major bleeding during treatment with dabigatran or warfarin. <i>Circulation</i> , 2013 , 128, 2325-32	16.7	222
345	Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. <i>Canadian Journal of Cardiology</i> , 2013 , 29, S34-44	3.8	31
344	Stroke prevention in atrial fibrillation patients with chronic kidney disease. <i>Canadian Journal of Cardiology</i> , 2013 , 29, S71-8	3.8	58
343	Edoxaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2013 , 369, 2093-104	59.2	3215
342	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013 , 128, 237-43	16.7	166
341	The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. <i>BMC Geriatrics</i> , 2013 , 13, 88	4.1	32
340	Anticoagulation in Patients Aged ≥55 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. <i>Cardiology and Therapy</i> , 2013 , 2, 135-49	2.8	28
339	Genetic determinants of dabigatran plasma levels and their relation to bleeding. <i>Circulation</i> , 2013 , 127, 1404-12	16.7	174
338	Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>Circulation</i> , 2013 , 127, 634-40	16.7	387
337	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 295-301	5.1	53
336	Low-dose colchicine for secondary prevention of cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2013 , 61, 404-410	15.1	501
335	Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013 , 6, 31-8	6.4	20
334	Anticoagulation management in patients with mechanical heart valves having pacemaker or defibrillator insertion. <i>Thrombosis Research</i> , 2013 , 131, 300-3	8.2	2
333	Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 224-8	3.8	64
332	Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 900-8	15.1	48
331	Procoagulants for management of bleeding with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1	7	1
330	Anticoagulant therapy in acute brain ischaemia. <i>Lancet Neurology</i> , 2013 , 12, 526-7	24.1	5
329	Anti-PF4/heparin antibodies and venous graft occlusion in postcoronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 253-60	15.4	9

328	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013 , 34, 170-6	9.5	134
327	Aspirin for preventing venous thromboembolism. <i>New England Journal of Medicine</i> , 2013 , 368, 773	59.2	4
326	Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. <i>Stroke</i> , 2013 , 44, 2232-9	6.7	53
325	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013 , 34, 2752-9	9.5	20
324	Stroke prevention in older adults with atrial fibrillation. <i>Cmaj</i> , 2013 , 185, 1479-80	3.5	4
323	Response to letters regarding article, Beriprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial. <i>Circulation</i> , 2013 , 127, e506	16.7	2
322	Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. <i>Circulation</i> , 2013 , 128, 2192-201	16.7	206
321	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013 , 34, 1498-505	9.5	97
320	Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 778-82	15.4	8
319	A guide to GRADE guidelines for the readers of JTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 1603-8	15.4	25
318	Processed residual pump blood in cardiac surgery: the Processed Residual Blood in Cardiac surgery trial. <i>Transfusion</i> , 2013 , 53, 1487-92	2.9	7
317	A response to--there's madness in their methods. <i>Journal of Thrombosis and Haemostasis</i> , 2013 , 11, 785-6	5.4	
316	Association of atrial fibrillation with mortality and disability after ischemic stroke. <i>Neurology</i> , 2013 , 81, 825-32	6.5	86
315	Is there really misuse and abuse of dabigatran?. <i>Medical Journal of Australia</i> , 2013 , 198, 358-9	4	3
314	Venous Thrombosis 2013 , 619-626		
313	Exposure To ABO Compatible But Non-Group Identical Blood and In-Hospital Mortality. <i>Blood</i> , 2013 , 122, 3651-3651	2.2	
312	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , 2012 , 11, 225-31	24.1	132
311	Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2012 , 11, 512-20	24.1	57

310	Reducing the risk of recurrent stroke in patients with AF. <i>Lancet Neurology, The</i> , 2012 , 11, 479-81	24.1	2
309	The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. <i>Transfusion</i> , 2012 , 52, 1203-12	2.9	47
308	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. <i>Transfusion</i> , 2012 , 52, 1363-78	2.9	8
307	Randomized controlled trial of a new portable calf compression device (Venowave) for prevention of venous thrombosis in high-risk neurosurgical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 229-35	15.4	22
306	Reversal of the anti-platelet effects of aspirin and clopidogrel. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 521-8	15.4	87
305	Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 966-8	15.4	7
304	The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?. <i>International Journal of Stroke</i> , 2012 , 7, 139-41	6.3	6
303	Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves. <i>American Journal of Hematology</i> , 2012 , 87 Suppl 1, S100-7	7.1	4
302	Preventing cardioembolic stroke in atrial fibrillation with dabigatran. <i>Current Neurology and Neuroscience Reports</i> , 2012 , 12, 17-23	6.6	8
301	Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 33, 88-94	5.1	80
300	Idrabiotaparinux treatment for venous thromboembolism. <i>Lancet, The</i> , 2012 , 379, 96-8	40	1
299	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. <i>European Heart Journal</i> , 2012 , 33, 2143-50	9.5	73
298	Translational success stories: development of direct thrombin inhibitors. <i>Circulation Research</i> , 2012 , 111, 920-9	15.7	50
297	Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. <i>Lancet Neurology, The</i> , 2012 , 11, 1066-81	24.1	62
296	Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 429-36	5.1	12
295	Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012 , 21, 429-35	2.8	79
294	Subtle differences in commercial heparins can have serious consequences for cardiopulmonary bypass patients: A randomized controlled trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 144, 944-950.e3	1.5	12
293	Cardiology patient page: Aspirin. <i>Circulation</i> , 2012 , 125, e439-42	16.7	14

292	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012 , 129, 715-9	8.2	32
291	Aspirin response variability after major orthopedic surgery. <i>Thrombosis Research</i> , 2012 , 130, 216-20	8.2	11
290	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012 , 119, 2172-4	2.2	191
289	Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. <i>Stroke</i> , 2012 , 43, 2221-7	6.7	70
288	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). <i>American Heart Journal</i> , 2012 , 163, 931-937.e1	4.9	139
287	Dabigatran for patients with a mechanical valve. <i>Heart Lung and Circulation</i> , 2012 , 21, 121; author reply 121-2	1.8	
286	Anticoagulation therapy. Dabigatran and risk of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012 , 9, 260-2	14.8	23
285	Anticoagulants in atrial fibrillation patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2012 , 8, 569-78	14.9	62
284	Low-dose aspirin for preventing recurrent venous thromboembolism. <i>New England Journal of Medicine</i> , 2012 , 367, 1979-87	59.2	358
283	The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by "true" heparin-induced thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 998-1000		3
282	Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. <i>Thrombosis and Haemostasis</i> , 2012 , 107, 8-14	7	13
281	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1228-35	7	20
280	Direct thrombin inhibitors in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2012 , 9, 402-14	14.8	24
279	Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e89S-e119S	5.3	262
278	Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, 53S-70S	5.3	177
277	Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. <i>Circulation</i> , 2012 , 126, 343-8	16.7	409
276	Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. <i>Journal of Internal Medicine</i> , 2012 , 271, 15-24	10.8	39
275	Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. <i>Circulation</i> , 2012 , 126, 2208-16	16.7	108

274	Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. <i>Circulation</i> , 2012 , 125, 669-76	16.7	306
273	The aspirin controversy in primary prevention. <i>Current Opinion in Cardiology</i> , 2012 , 27, 499-507	2.1	22
272	Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2012 , 27, 331-9	2.1	9
271	Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012 , 5, 250-6		21
270	More on acutely injured patients receiving dabigatran. <i>New England Journal of Medicine</i> , 2012 , 366, 863; author reply 864	59.2	5
269	Anticoagulants in patients with atrial fibrillation and end-stage renal disease. <i>Postgraduate Medicine</i> , 2012 , 124, 17-25	3.7	8
268	Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial. <i>Expert Review of Cardiovascular Therapy</i> , 2012 , 10, 965-72	2.5	7
267	Reply to Letters Regarding Article, Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. <i>Circulation</i> , 2012 , 125,	16.7	2
266	Periprocedural management and approach to bleeding in patients taking dabigatran. <i>Circulation</i> , 2012 , 126, 2428-32	16.7	95
265	Sex, stroke, and atrial fibrillation. <i>Archives of Neurology</i> , 2012 , 69, 1641-3		11
264	Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial. <i>Stroke</i> , 2012 , 43, 1572-7	6.7	17
263	Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". <i>Stroke</i> , 2012 , 43, e46-7; author reply e49	6.7	
262	B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITamins TO Prevent Stroke (VITATOPS) MRI-substudy. <i>Stroke</i> , 2012 , 43, 3266-70	6.7	58
261	Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?. <i>Stroke</i> , 2012 , 43, 2048-54	6.7	31
260	New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e1205-e1515	5.3	170
259	REVERSAL OF THE ANTI-PLATELET EFFECTS OF ASPIRIN AND CLOPIDOGREL. <i>Heart</i> , 2012 , 98, E272.2-E273.2	3.1	
258	Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e185S-e194S	5.3	131
257	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , 2012 , 120, 19-19	2.2	6

256	The reemergence of aspirin for the prevention of venous thromboembolism. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 120-1	0.6	3
255	Overexpression of the multidrug resistance protein-4 transporter in patients undergoing coronary artery bypass graft surgery a cause of aspirin resistance?. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 762-4	15.1	8
254	Apixaban in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 364, 806-17	59.2	1772
253	Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 572-84	7	152
252	Effect of aspirin on mortality in the primary prevention of cardiovascular disease. <i>American Journal of Medicine</i> , 2011 , 124, 621-9	2.4	108
251	Use of clopidogrel post-coronary artery bypass surgery in canadian patients with acute coronary syndromes. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 711-5	3.8	9
250	Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. <i>Annual Review of Medicine</i> , 2011 , 62, 41-57	17.4	149
249	Apixaban in acute coronary syndromes. <i>Cardiovascular Therapeutics</i> , 2011 , 29, 285-90	3.3	3
248	Double-dose clopidogrel in patients undergoing PCI for ACS [Authors' reply]. <i>Lancet, The</i> , 2011 , 377, 298	40	1
247	Should adult patients be routinely tested for heritable thrombophilia after an episode of venous thromboembolism?. <i>Medical Journal of Australia</i> , 2011 , 195, 139-42	4	5
246	New anticoagulants for atrial fibrillation: the beginning of a a new era in stroke prevention. <i>Canadian Journal of Neurological Sciences</i> , 2011 , 38, 777-82	1	
245	Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. <i>Annals of Internal Medicine</i> , 2011 , 155, 660-7, W204	8	157
244	Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. <i>Annals of Internal Medicine</i> , 2011 , 155, 579-86	8	97
243	Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 2389-96	15.4	99
242	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 378-85	5.1	10
241	Chills and limb pain following administration of low-molecular-weight heparin for treatment of acute venous thromboembolism. <i>American Journal of Hematology</i> , 2011 , 86, 603-6	7.1	8
240	Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 279-86	2.5	14
239	Dabigatran etexilate: a new oral thrombin inhibitor. <i>Circulation</i> , 2011 , 123, 1436-50	16.7	284

238	Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. <i>Blood Reviews</i> , 2011 , 25, 123-9	11.1	31
237	New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. <i>BMJ, The</i> , 2011 , 342, c7270	5.9	10
236	Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. <i>Circulation</i> , 2011 , 123, 2736-47	16.7	2467
235	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 522-34	6	88
234	Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin. <i>Cerebrovascular Diseases</i> , 2011 , 32, 22-7	3.2	6
233	New oral anticoagulants for stroke prevention in atrial fibrillation. <i>Clinical Investigation</i> , 2011 , 1, 3-7		2
232	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. <i>European Heart Journal</i> , 2011 , 32, 2256-65	9.5	34
231	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011 , 32, 1854-64	9.5	273
230	Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. <i>Circulation</i> , 2011 , 123, 2363-72	16.7	872
229	Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 505-13; discussion 513	6	14
228	Testing should not be done in all patients treated with clopidogrel who are undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 514-21; discussion 521	6	18
227	Oral antiplatelet therapy 2011 , 311-319		
226	The CHADS2 score for stroke risk stratification in atrial fibrillation—friend or foe?. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 45-8	7	101
225	Explaining the RE-LY Trial. <i>Canadian Journal of Hospital Pharmacy</i> , 2010 , 63, 334-6	0.5	
224	Another oral thrombin inhibitor for stroke prevention in atrial fibrillation?. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 481-3	7	4
223	Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 382-7	9.4	30
222	Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. <i>Circulation</i> , 2010 , 121, 1188-99	16.7	372
221	Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. <i>Circulation</i> , 2010 , 121, 2067-70	16.7	92

220	New anticoagulants. <i>Circulation</i> , 2010 , 121, 1523-32	16.7	227
219	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010 , 31, 50-8	9.5	64
218	Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. <i>New England Journal of Medicine</i> , 2010 , 363, 930-42	59.2	582
217	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. <i>New England Journal of Medicine</i> , 2010 , 363, 1704-14	59.2	428
216	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010 , 125, e128-31	8.2	9
215	Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>American Heart Journal</i> , 2010 , 159, 348-353.e1	4.9	118
214	Duration of red cell storage before transfusion and in-hospital mortality. <i>American Heart Journal</i> , 2010 , 159, 737-743.e1	4.9	81
213	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. <i>American Heart Journal</i> , 2010 , 160, 1178-84	4.9	78
212	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. <i>American Heart Journal</i> , 2010 , 160, 1049-55	4.9	9
211	DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2010 , 55, A1.E2	15.1	6
210	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , 2010 , 376, 1233-43	40	624
209	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet, The</i> , 2010 , 376, 975-83	40	754
208	New antithrombotic agents--insights from clinical trials. <i>Nature Reviews Cardiology</i> , 2010 , 7, 498-509	14.8	36
207	The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. <i>Stroke</i> , 2010 , 41, 2398-9	6.7	15
206	Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease. <i>Future Cardiology</i> , 2010 , 6, 289-99	1.3	8
205	Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 127-32	5.1	20
204	Mortality and morbidity following a major bleed in a registry population with acute ST elevation myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 434-40	5.1	27
203	Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. <i>Lancet Neurology, The</i> , 2010 , 9, 273-84	24.1	72

202	B vitamins in patients with recent transient ischaemic attack or stroke in the VITamins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2010 , 9, 855-65	24.1	228
201	A national survey of Canadian practice patterns of warfarin after anterior wall myocardial infarction in the current era of dual antiplatelet therapy. <i>American Journal of Cardiology</i> , 2010 , 105, 1844	3	5
200	Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 148-56	15.4	655
199	Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 101-6	15.4	66
198	Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 243-9	15.4	33
197	How can we reduce disagreement among guidelines for venous thromboembolism prevention?. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 675-7	15.4	4
196	Does dabigatran improve stroke-prevention in atrial fibrillation? Reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1438-1439	15.4	2
195	A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1966-75	15.4	61
194	Systematic Review to Identify Validated Manual Warfarin Maintenance Dosing Tools.. <i>Blood</i> , 2010 , 116, 3800-3800	2.2	1
193	Low-molecular-weight heparin as an adjunct to thrombolysis in ST elevation myocardial infarction. <i>Archives of Internal Medicine</i> , 2009 , 169, 1163-4		5
192	Anticoagulation for ST-segment elevation myocardial infarction. <i>Circulation</i> , 2009 , 119, 1186-8	16.7	4
191	Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. <i>Circulation</i> , 2009 , 120, 2006-11	16.7	64
190	Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. <i>Circulation</i> , 2009 , 120, 1108-14	16.7	55
189	Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial. <i>Cerebrovascular Diseases</i> , 2009 , 27, 259-65	3.2	31
188	Response to Letter Regarding Article, Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk. <i>Circulation</i> , 2009 , 119,	16.7	1
187	New anticoagulants for atrial fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 515-24	5.3	42
186	Ethnicity does not affect the homocysteine-lowering effect of B-vitamin therapy in Singaporean stroke patients. <i>Stroke</i> , 2009 , 40, 2209-11	6.7	7
185	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention. <i>American Journal of Hematology</i> , 2009 , 84, 579-83	7.1	12

184	New pharmacotherapy for stroke prevention in atrial fibrillation: update 2010. <i>Advances in Therapy</i> , 2009 , 26, 1058-71	4.1	8
183	Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism?. <i>British Journal of Haematology</i> , 2009 , 146, 142-9	4.5	34
182	Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009 , 32, 378-82	1.6	77
181	Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. <i>Thrombosis Research</i> , 2009 , 123, 687-96	8.2	244
180	Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary Intervention in Acute coronary Lesions (PRACTICAL) Trial. <i>American Heart Journal</i> 2009 , 157, 60.e1-9	4.9	15
179	Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. <i>American Heart Journal</i> , 2009 , 158, 881-886.e1	4.9	27
178	Dabigatran versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2009 , 361, 1139-51	59.2	7909
177	Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 241-9	2.5	5
176	Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. <i>Canadian Journal of Cardiology</i> , 2009 , 25, 683-9	3.8	63
175	Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. <i>Lancet, The</i> , 2009 , 374, 565-76	4.0	151
174	Otamixaban in acute coronary syndromes. <i>Lancet, The</i> , 2009 , 374, 762-4	4.0	7
173	Rivaroxaban versus enoxaparin after total knee arthroplasty. <i>Lancet, The</i> , 2009 , 374, 681; author reply 683	4.0	3
172	Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. <i>Annals of Internal Medicine</i> , 2009 , 150, 379-86	8	126
171	American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?. <i>Chest</i> , 2009 , 135, 513-520	5.3	172
170	Deep Vein Thrombosis Prophylaxis: Response. <i>Chest</i> , 2009 , 136, 1700-1701	5.3	2
169	ACP Journal Club: Percutaneous closure of the left atrial appendage was noninferior to warfarin in atrial fibrillation. <i>Annals of Internal Medicine</i> , 2009 , 151, JC5-10	8	
168	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2009 , 30, 655-61	9.5	121
167	Treatment of intermittent claudication. <i>BMJ, The</i> , 2009 , 338, b46	5.9	2

166	Dabigatran etexilate for prevention of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2009 , 101, 2-4	7	20
165	New oral anticoagulants: not quite there yet. <i>Polish Archives of Internal Medicine</i> , 2009 , 119, 53-59	1.9	2
164	Anticoagulation in Acute Coronary Syndromes. <i>Fundamental and Clinical Cardiology</i> , 2009 , 171-196		
163	Clinical factors influencing the sensitivity to warfarin when restarted after surgery. <i>Journal of Internal Medicine</i> , 2008 , 263, 412-9	10.8	10
162	The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2008 , 8, 24	2.3	43
161	What do the results of the PROfESS trial teach us?. <i>Lancet Neurology</i> , 2008 , 7, 860-2	24.1	7
160	Guidelines for anticoagulant use in acute coronary syndromes. <i>Lancet</i> , 2008 , 371, 1559-61	40	12
159	Selective factor Xa inhibition for thromboprophylaxis. <i>Lancet</i> , 2008 , 372, 6-8	40	7
158	Guidelines for anticoagulant use in acute coronary syndromes [Authors' reply]. <i>Lancet</i> , 2008 , 372, 533-534	40	1
157	Gastrointestinal bleeding after acute ischemic stroke. <i>Neurology</i> , 2008 , 71, 650-5	6.5	59
156	Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008 , 5, 766-80		72
155	Homocysteine or renal impairment: which is the real cardiovascular risk factor?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 1158-64	9.4	62
154	Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. <i>Circulation</i> , 2008 , 118, 2029-37	16.7	670
153	Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. <i>Stroke</i> , 2008 , 39, 1638-46	6.7	40
152	The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. <i>European Heart Journal</i> , 2008 , 29, 1057-71	9.5	121
151	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. <i>Circulation</i> , 2008 , 118, 2038-46	16.7	76
150	Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. <i>Circulation</i> , 2008 , 118, 1705-12	16.7	174
149	Effect of fondaparinux 2.5 mg once daily on mortality: a meta-analysis of phase III randomized trials of venous thromboembolism prevention. <i>Country Review Ukraine</i> , 2008 , 10, C8-C13		7

148	The risk of iatrogenic bleeding in acute coronary syndromes and long-term mortality. <i>Current Opinion in Cardiology</i> , 2008 , 23, 327-34	2.1	14
147	Management of peripheral arterial disease in the elderly: focus on cilostazol. <i>Clinical Interventions in Aging</i> , 2008 , 3, 17-23	4	10
146	The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. <i>Medical Journal of Australia</i> , 2008 , 189, 144-7	4	61
145	Using aspirin to prevent cognitive decline. <i>BMJ, The</i> , 2008 , 337, a958	5.9	4
144	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1742-51	15.1	203
143	Guidelines for the management of acute coronary syndromes 2006. <i>Medical Journal of Australia</i> , 2007 , 186, 101; discussion 101-2	4	
142	Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5 Suppl 1, 255-63	15.4	64
141	Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. <i>Journal of Thrombosis and Haemostasis</i> , 2007 , 5, 1438-43	15.4	90
140	VITATOPS, the VITAMINS TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). <i>International Journal of Stroke</i> , 2007 , 2, 144-50	6.3	33
139	Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. <i>Clinical Cardiology</i> , 2007 , 30, 1124-34	3.3	38
138	Role of protein z in stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2007 , 9, 191-7	2.1	2
137	Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2007 , 28, 1193-204	9.5	216
136	A replacement for warfarin: the search continues. <i>Circulation</i> , 2007 , 116, 131-3	16.7	36
135	Challenges of establishing new antithrombotic therapies in atrial fibrillation. <i>Circulation</i> , 2007 , 116, 449-55	5.7	74
134	Inherited thrombophilia and pregnancy associated venous thromboembolism. <i>BMJ, The</i> , 2007 , 334, 1318-21	5.21	33
133	Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. <i>New England Journal of Medicine</i> , 2007 , 357, 217-27	59.2	287
132	Treatment of restenosis with a paclitaxel-coated balloon catheter. <i>New England Journal of Medicine</i> , 2007 , 356, 1071; author reply 1072-3	59.2	2
131	Platelet function testing: quality assurance. <i>Seminars in Thrombosis and Hemostasis</i> , 2007 , 33, 273-82	5.3	58

130	Latest medical treatment strategies for venous thromboembolism. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 1221-33	4	9
129	Antithrombotic treatment for peripheral arterial disease. <i>Heart</i> , 2007 , 93, 303-8	5.1	16
128	Beyond unfractionated heparin and warfarin: current and future advances. <i>Circulation</i> , 2007 , 116, 552-60	16.7	178
127	Pexelizumab and the APEX AMI Trial Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1877	27.4	
126	Anticoagulation for venous thromboembolism. <i>BMJ, The</i> , 2007 , 334, 645	5.9	5
125	Who is (still) getting HIT?. <i>Chest</i> , 2007 , 131, 1620-2	5.3	22
124	Aspirin resistance. <i>Thrombosis Research</i> , 2007 , 120, 337-46	8.2	45
123	Nonbleeding complications of unfractionated and low-molecular weight heparins. <i>Clinical Advances in Hematology and Oncology</i> , 2007 , 5, 871-3	0.6	1
122	Bleeding and management of bleeding. <i>Country Review Ukraine</i> , 2006 , 8, G38-G45		50
121	Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. <i>Stroke</i> , 2006 , 37, 456-60	6.7	30
120	Management of antiphospholipid antibody syndrome: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1050-7	27.4	291
119	Treatment of Antiphospholipid Antibody Syndrome Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 42	27.4	2
118	Association between phosphodiesterase 4D gene and ischaemic stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1067-9	5.5	55
117	Medical treatment of peripheral arterial disease. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 547-53	27.4	231
116	Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. <i>Archives of Internal Medicine</i> , 2006 , 166, 729-36		200
115	The Outpatient Bleeding Risk Index predicted major bleeding in patients taking warfarin. <i>Evidence-Based Medicine</i> , 2006 , 11, 120		
114	Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. <i>Annals of Internal Medicine</i> , 2006 , 144, 673-84	8	289
113	Aspirin resistance. <i>Lancet, The</i> , 2006 , 367, 606-17	40	433

112	ESPRIT trial. <i>Lancet, The</i> , 2006 , 368, 447; author reply 449		40
111	Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. <i>Circulation</i> , 2006 , 114, 774-82	16.7	1020
110	Monitoring unfractionated heparin with the aPTT: Time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 547-552	7	110
109	Homocysteine--should we screen and treat in preventive cardiology programs?. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2006 , 26, 281-7		
108	The tissue factor pathway in ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , 2006 , 17, 527-32	1	13
107	More on: enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1639-1640	15.4	1
106	Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI). <i>Vascular Health and Risk Management</i> , 2006 , 2, 379-87	4.4	3
105	Aspirin resistance: does it exist and is it an important clinical problem?. <i>Clinical Advances in Hematology and Oncology</i> , 2006 , 4, 268-70	0.6	
104	Monitoring unfractionated heparin with the aPTT: time for a fresh look. <i>Thrombosis and Haemostasis</i> , 2006 , 96, 547-52	7	45
103	Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. <i>Stroke</i> , 2005 , 36, 144-6	6.7	76
102	Protein Z gene polymorphisms, protein Z concentrations, and ischemic stroke. <i>Stroke</i> , 2005 , 36, 1123-7	6.7	45
101	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005 , 26, 2396-403	9.5	21
100	High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1094-5	15.4	17
99	Aspirin resistance: position paper of the Working Group on Aspirin Resistance. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1309-11	15.4	276
98	Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 2649-55	15.4	45
97	Bone marrow biopsy in thrombocytopenic or anticoagulated patients. <i>British Journal of Haematology</i> , 2005 , 129, 562-3	4.5	12
96	RE: Bain B.J. (2004) Bone marrow biopsy morbidity and mortality: 2002 data. Clinical and Laboratory Haematology 26, 315-318. <i>International Journal of Laboratory Hematology</i> , 2005 , 27, 209-10		1
95	Von Willebrand disease associated with superficial temporal artery pseudoaneurysm. <i>European Journal of Vascular and Endovascular Surgery</i> , 2005 , 30, 285-7	2.3	7

94	Venous thromboembolism: diagnosis and management of deep venous thrombosis. <i>Medical Journal of Australia</i> , 2005 , 182, 476-81	4	29
93	Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions. <i>Medical Journal of Australia</i> , 2005 , 182, 199-199	4	0
92	Venous thromboembolism: diagnosis and management of pulmonary embolism. <i>Medical Journal of Australia</i> , 2005 , 183, 220-221	4	
91	Venous thromboembolism: diagnosis and management of pulmonary embolism. <i>Medical Journal of Australia</i> , 2005 , 182, 569-74	4	19
90	Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks. <i>Neurology</i> , 2005 , 64, 1117-21	6.5	15
89	Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. <i>Circulation</i> , 2005 , 112, 3855-67	16.7	109
88	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005 , 83, 98-103	2.4	13
87	Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population. <i>Cerebrovascular Diseases</i> , 2005 , 19, 110-6	3.2	11
86	Low Molecular Weight Heparin and Bleeding in Patients with Severe Renal Failure: A Meta-Analysis.. <i>Blood</i> , 2005 , 106, 907-907	2.2	0
85	Homocysteine and stroke. <i>Lancet, The</i> , 2005 , 365, 194-6	40	15
84	Clinical usefulness of plasma homocysteine in vascular disease. <i>Medical Journal of Australia</i> , 2004 , 181, 314-8	4	38
83	Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. <i>Medical Journal of Australia</i> , 2004 , 181, 150-4	4	70
82	The beginning of the end of warfarin?. <i>Medical Journal of Australia</i> , 2004 , 180, 549-51	4	7
81	Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 493-503	4	14
80	Red cell N5-methyltetrahydrofolate concentrations and C677T methylenetetrahydrofolate reductase genotype in patients with stroke. <i>Journal of Clinical Pathology</i> , 2004 , 57, 54-7	3.9	8
79	Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?. <i>Stroke</i> , 2004 , 35, 389-91	17	13
78	Folic acid-based multivitamin therapy to prevent stroke: the jury is still out. <i>Stroke</i> , 2004 , 35, 1995-8	6.7	5
77	Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. <i>Journal of Thrombosis and Haemostasis</i> , 2004 , 2, 2067-9	15.4	35

76	Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice. <i>American Journal of Cardiovascular Drugs</i> , 2004 , 4, 57-67	4	25
75	Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction. <i>American Journal of Cardiovascular Drugs</i> , 2004 , 4, 107-15	4	3
74	Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. <i>Circulation</i> , 2004 , 110, 744-9	16.7	451
73	Ximelagatran or warfarin in atrial fibrillation?. <i>Lancet, The</i> , 2004 , 363, 734; author reply 734, 736	40	6
72	Renal Function, Peak Anti-Xa Levels and Enoxaparin Dosing. <i>Journal of Pharmacy Practice and Research</i> , 2004 , 34, 14-17	0.7	5
71	Is there a role for laboratory testing to identify patients at risk of aspirin treatment failure?. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 129-30	1	2
70	Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 353-7	1	4
69	Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. <i>Annals of Internal Medicine</i> , 2004 , 140, 175-83	8	260
68	High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in antiphospholipid antibody syndrome. <i>ACP Journal Club</i> , 2004 , 140, 38		1
67	Thromboprophylaxis practice patterns in two Western Australian teaching hospitals. <i>Haematologica</i> , 2004 , 89, 586-93	6.6	17
66	High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome. <i>ACP Journal Club</i> , 2004 , 140, 38		
65	Editorial comment--Routine thrombophilia testing in stroke patients is unjustified. <i>Stroke</i> , 2003 , 34, 1826-7	6.7	13
64	Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. <i>Stroke</i> , 2003 , 34, 2132-7	6.7	127
63	Protein Z in ischemic stroke and its etiologic subtypes. <i>Stroke</i> , 2003 , 34, 2415-9	6.7	62
62	Antiplatelet agents in acute coronary syndromes. <i>Seminars in Vascular Medicine</i> , 2003 , 3, 403-14		4
61	Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?. <i>Stroke</i> , 2003 , 34, 2736-40	6.7	17
60	Recombinant activated factor VII for the treatment of life-threatening haemorrhage. <i>Blood Coagulation and Fibrinolysis</i> , 2003 , 14, 713-7	1	66
59	Venous thromboembolism in travellers. <i>Blood Coagulation and Fibrinolysis</i> , 2003 , 14, 671-675	1	20

58	In reply: Low-molecular-weight heparins and heparinoids. <i>Medical Journal of Australia</i> , 2003 , 178, 414-415		
57	Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 963-70	15.4	34
56	Suboptimal preventive practices in patients with carotid and peripheral vascular occlusive disease in a tertiary referral setting. <i>ANZ Journal of Surgery</i> , 2003 , 73, 932-7	1	8
55	Thromboprophylaxis practice patterns in hip fracture surgery patients: experience in Perth, Western Australia. <i>ANZ Journal of Surgery</i> , 2003 , 73, 826-9	1	7
54	Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 2689-91	15.4	38
53	The evolving role of direct thrombin inhibitors in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 70S-78S	15.1	32
52	Aspirin resistance: a new independent predictor of vascular events?. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 966-8	15.1	98
51	C-reactive protein in ischemic stroke and its etiologic subtypes. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2003 , 12, 74-81	2.8	31
50	Does this patient have pulmonary embolism?. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 290, 2849-58	27.4	105
49	Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. <i>ACP Journal Club</i> , 2003 , 138, 33		1
48	Review: MTHFR TT genotype increases risk for coronary heart disease. <i>ACP Journal Club</i> , 2003 , 138, 79		
47	Homocysteine-lowering therapy improved outcomes after percutaneous coronary intervention. <i>ACP Journal Club</i> , 2003 , 138, 33		1
46	Review: MTHFR TT genotype increases risk for coronary heart disease. <i>ACP Journal Club</i> , 2003 , 138, 79		
45	Low molecular weight heparins and heparinoids. <i>Medical Journal of Australia</i> , 2002 , 177, 379-83	4	39
44	Recurrent palmar-plantar erythrodysesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2002 , 69, 315-7	3.8	11
43	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. <i>Circulation</i> , 2002 , 105, 1650-5	16.7	907
42	Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndrome undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2002 , 23, 117-23	9.5	19
41	Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2002 , 23, 1771-9	9.5	53

40	Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. <i>New England Journal of Medicine</i> , 2002 , 346, 1589-90; author reply 1589-90	59.2	4
39	Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. <i>Archives of Internal Medicine</i> , 2002 , 162, 1465-71		136
38	Management of patients with acute coronary syndromes: what is the clinical role of direct thrombin inhibitors?. <i>Drugs</i> , 2002 , 62, 1839-52	12.1	5
37	Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. <i>Lancet, The</i> , 2002 , 359, 294-302	40	209
36	The tip of the iceberg?. <i>Lancet, The</i> , 2002 , 359, 2194	40	1
35	Direct thrombin inhibitors in acute coronary syndromes. <i>Lancet, The</i> , 2002 , 360, 492	40	2
34	Design of trials to evaluate antiplatelet agents 2002 , 1003-1012		
33	Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. <i>Blood</i> , 2001 , 98, 36-40	2.2	78
32	Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. <i>Stroke</i> , 2001 , 32, 1793-9	6.7	104
31	Homocysteine and stroke. <i>Current Opinion in Neurology</i> , 2001 , 14, 95-102	7.1	83
30	Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 285, 444-50	27.4	20
29	Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. <i>Circulation</i> , 2001 , 103, 643-50	16.7	40
28	Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 37-43	15.1	306
27	Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. <i>Lancet, The</i> , 2001 , 358, 9-15	40	416
26	Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications. <i>CNS Drugs</i> , 2001 , 15, 437-43	6.7	19
25	Routine home treatment of deep vein thrombosis. <i>BMJ: British Medical Journal</i> , 2001 , 322, 1192-3		14
24	Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2001 , 10, 377-83	3.5	15
23	Detection of protein S deficiency: a new functional assay compared to an antigenic technique. <i>Pathology</i> , 2000 , 32, 94-7	1.6	3

22	The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. <i>European Heart Journal</i> , 2000 , 21, 2033-41	9.5	199
21	Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. <i>Stroke</i> , 2000 , 31, 1069-75	6.7	194
20	Management of unstable angina and myocardial infarction. <i>Lancet, The</i> , 2000 , 356, 1193-1194	4.0	1
19	Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , 2000 , 356, 1850	4.0	2
18	Enoxaparin was superior to heparin in preventing serious cardiac ischemic events in patients with unstable angina/non-Q-wave MI. <i>Evidence-based Cardiovascular Medicine</i> , 2000 , 4, 45		
17	Management of unstable coronary-artery disease. <i>Lancet, The</i> , 2000 , 355, 572; author reply 573-4	4.0	1
16	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet, The</i> , 2000 , 355, 1936-42	4.0	343
15	Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. <i>Lancet, The</i> , 2000 , 356, 449-54	4.0	60
14	Homocyst(e)ine and Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2000 , 132, 676	8	1
13	Antiplatelet drugs. <i>Medical Journal of Australia</i> , 1999 , 170, 379-82	4	44
12	Preventing thromboembolic complications in older orthopaedic surgery patients: interventions and outcomes. <i>Drugs and Aging</i> , 1999 , 15, 297-306	4.7	2
11	Homocysteine and vascular disease. <i>Lancet, The</i> , 1999 , 354, 407-13	4.0	75 ⁸
10	Homocysteine and cardiovascular risk: is it time to treat?. <i>Evidence-based Cardiovascular Medicine</i> , 1999 , 3, 59-60		
9	Broadsheet number 53: Activated protein C resistance: diagnosis and clinical management. <i>Pathology</i> , 1999 , 31, 365-71	1.6	
8	Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. <i>Annals of Internal Medicine</i> , 1999 , 131, 363-75	8	627
7	Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma. <i>American Journal of Hematology</i> , 1998 , 59, 260-1	7.1	13
6	Venous thrombosis and hyperhomocysteinaemia. <i>Medical Journal of Australia</i> , 1998 , 169, 313-5	4	3
5	Exacerbation of coagulopathy with concurrent bone marrow necrosis, hepatic and renal dysfunction secondary to all-trans retinoic acid therapy for acute promyelocytic leukemia. <i>Hematological Oncology</i> , 1997 , 15, 13-7	1.3	2

4 Cyclooxygenase Inhibitors 31-46

3 Oral anticoagulation versus antiplatelet therapy for secondary stroke prevention in patients with embolic stroke of undetermined source: A systematic review and meta-analysis. *European Stroke Journal*, 239698732210769 5.6 0

2 Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials 3

1 Thrombolytic Therapy for Deep Vein Thrombosis and Pulmonary Embolism 88-98